NCT05979909View on ClinicalTrials.gov

Intravesical Mitomycin C After Diagnostic Ureteroscopy for Upper Tract Urothelial Carcinoma

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 30, 2023

Primary Completion Date

September 30, 2025

Study Completion Date

September 30, 2027

Conditions
Urothelial Carcinoma UreterUrothelial Cancer of Renal Pelvis
Interventions
DRUG

Mitomycin C

Mitomycin (40 mg in 40 mL of sterile water) will be administered through a Foley catheter, which will be clamped for two hours.

All Listed Sponsors
lead

McMaster University

OTHER

NCT05979909 - Intravesical Mitomycin C After Diagnostic Ureteroscopy for Upper Tract Urothelial Carcinoma | Biotech Hunter | Biotech Hunter